Related Experiment Video
Updated: May 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Optimal treatment with telaprevir for chronic HCV infection
Arun B Jesudian1, Ira M Jacobson
1Division of Gastroenterology and Hepatology, Center for Study of Hepatitis C, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA.
Abstract:
Telaprevir is a recently approved direct-acting antiviral against hepatitis C virus (HCV) that works through inhibition of the NS3/4A serine protease inhibitor.Phase 2b and 3 studies have shown marked increase in sustained virological response rates in both treatment-naïve and treatment-experienced patients with HCV genotype 1 treated with a telaprevir-containing regimen compared with pegylated interferon (PEG-IFN) and ribavirin alone. The most commonly observed side effects of telaprevir therapy are anaemia to a greater degree than that observed with PEG-IFN/ribavirin alone; eczematous rash, which can be severe in a minority of patients; and anorectal discomfort.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Viral Hepatitis I: Introduction
Retroviruses
Inhibitors of Viral Protein Synthesis

